BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6558419)

  • 21. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
    Koistinen V; Wessberg S; Leikola J
    Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
    Lambris JD; Müller-Eberhard HJ
    J Biol Chem; 1984 Oct; 259(20):12685-90. PubMed ID: 6567645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL; Isenman DE
    J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of factor B of the complement system by kallikrein and its light chain.
    Hiemstra PS; Daha MR; Bouma BN
    Thromb Res; 1985 Jun; 38(5):491-503. PubMed ID: 3848216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of the alternative pathway of human complement by C1q.
    Fishelson Z; Müller-Eberhard HJ
    Mol Immunol; 1987 Sep; 24(9):987-93. PubMed ID: 2958692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    Isenman DE; Podack ER; Cooper NR
    J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
    Jelezarova E; Vogt A; Lutz HU
    Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The inhibitory effect of factor J on the alternative complement pathway.
    González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
    J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formation of high-affinity C5 convertases of the alternative pathway of complement.
    Rawal N; Pangburn M
    J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A reexamination of the role of magnesium in the human alternative pathway of complement.
    Pryzdial EL; Isenman DE
    Mol Immunol; 1986 Jan; 23(1):87-96. PubMed ID: 3634188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymerization of factor B of the alternative complement pathway via disulfide bond(s) in the presence of Cu2+ and stimulation by C3b, the major fragment of C3.
    Matsushita M; Iwasaki A; Okada H
    Biochem Biophys Res Commun; 1989 Nov; 165(1):101-5. PubMed ID: 2590211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
    Rawal N; Pangburn MK
    Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
    Fishelson Z; Müller-Eberhard HJ
    Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.